Dr. Rule on the MabCute Study in Indolent Non-Hodgkin Lymphoma

Simon Rule, MD, PhD

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses results of the phase III MabCute study evaluating the efficacy and safety of subcutaneous rituximab (Rituxan) as maintenance after standard subcutaneous rituximab induction and maintenance in patients who have relapsed or refractory indolent non-Hodgkin lymphoma.

The study was conducted in 639 patients, and 129 progression-free survival after randomization (PFSrand) events were needed to achieve 80% power. The study was not able to fully address this primary endpoint of PFSrand due to the limited number of events observed.

However, the study did show that the safety profile of subcutaneous rituximab during prolonged maintenance was consistent with the known profile of the product, and also demonstrated that the safety profiles of the intravenous rituximab and the subcutaneous option were comparable.

  <<< 2019 European Hematology Association Congress
Printer Printing...